Cabaletta Bio, Inc. (CABA) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
CABA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CABA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CABA earnings history in CSV or JSON format
Free sign-in required to download data
Cabaletta Bio, Inc. (CABA) Earnings Overview
As of May 6, 2026, Cabaletta Bio, Inc. (CABA) reported trailing twelve-month net income of -$168M, reflecting +29.9% year-over-year growth. The company earned $-1.64 per diluted share over the past four quarters.
Looking at the long-term picture, CABA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$250,000 in fiscal 2017.
Cabaletta Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), IMVT (-$464M net income), ARQT (-$16M net income, -4.3% margin), CABA has comparable earnings metrics. Compare CABA vs KYMR →
CABA Earnings vs Peers
Earnings metrics vs comparable public companies
CABA Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$168M | -44.9% | -$172M | $-1.64 | - | - |
| 2024 | -$116M | -71.2% | -$125M | $-2.34 | - | - |
| 2023 | -$68M | -27.7% | -$75M | $-1.65 | - | - |
| 2022 | -$53M | -14.4% | -$54M | $-1.81 | - | - |
| 2021 | -$46M | -38.8% | -$46M | $-1.80 | - | - |
| 2020 | -$33M | -96.8% | -$34M | $-1.44 | - | - |
| 2019 | -$17M | -38.9% | -$19M | $-4.07 | - | - |
| 2018 | -$12M | -4780.8% | -$6M | $-0.84 | - | - |
| 2017 | $-250,000 | - | $-250,000 | $-0.01 | - | - |
See CABA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CABA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CABA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCABA — Frequently Asked Questions
Quick answers to the most common questions about buying CABA stock.
Is CABA growing earnings?
CABA EPS is $-1.64, with earnings growth accelerating to +29.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-168M.
What are CABA's profit margins?
Cabaletta Bio, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CABA's earnings?
CABA earnings data spans 2017-2025. The accelerating earnings trend is +29.9% YoY. Historical data enables comparison across business cycles.